Bottom line. Cigna’s second quarter showed that the portfolio can absorb a deliberate reset in Pharmacy Benefit Services without giving up consolidated earnings growth. PBS adjusted income fell 27% to $609M, yet Specialty and Care Services rose 22% to $1.05B and Cigna Healthcare rose 17% to $1.28B. Consolidated adjusted income increased 6% and adjusted EPS increased 8% to $7.78. That is meaningful validation of Cigna’s diversification. It is not yet proof that the businesses offsetting PBS can become sufficiently additive in 2027 to support the 10%-14% long-term EPS algorithm.
The quarter also cleared the July 29 hurdle on more than EPS. EPS beat by $0.18, or 2.4%; revenue of $71.67B was 2.2% above consensus; Evernorth and Cigna Healthcare adjusted operating income beat; and the 84.5% MCR was 50 basis points favorable to consensus. Despite the strong print, management raised the 2026 EPS floor by only $0.10, to $30.45—effectively matching the $30.46 preprint consensus. Said another way, the print protected the 2026 floor more than it lifted the earnings path, which is ultimately more important for valuation.
Sources: CI 2Q26 earnings release and financial supplement; StreetAccount; Graver Research calculations.
How CI absorbed the PBS reset
PBS adjusted income fell by $224M year-over-year, while Specialty and Care Services added $191M, offsetting approximately 85% of the decline and leaving Evernorth down only $33M. Cigna Healthcare contributed another $182M. Corporate and Other was a $32M drag, partially offset by $7M of lower tax expense. These changes reconcile to a $124M increase in consolidated adjusted income.
Sources: CI 2Q26 financial supplement; Graver Research calculations.
Share repurchases provided modest support to headline EPS growth. Diluted shares declined 1.6% year over year, adding roughly 1.6 percentage points to the 8% increase in adjusted EPS; adjusted income rose 6%. The $30.45 full-year EPS floor represents only about 2% growth from 2025 and already assumes additional share repurchases. The quarter therefore increased confidence that Cigna can deliver modest EPS growth through the PBS reset, but it did not establish a return to the company’s 10%–14% long-term algorithm.
The offsets are credible, but not a new run rate
Specialty growth looks like the most credible offset, but +22% year-over-year is not the right run rate. Management said some of the benefit from faster generic and biosimilar adoption arrived earlier than expected, and some economics shifted from PBS into Specialty. Those factors make the $191M increase real, but also limit its repeatability. Cigna’s long-term framework calls for 8%-12% Specialty adjusted-income growth, a more appropriate baseline than annualizing the second quarter. The question for 2027 is not whether Specialty can grow, but whether normalized high-single- to low-double-digit growth can still cover continued PBS pressure once earlier timing and the shift of economics out of PBS stop helping the comparison.
Cigna Healthcare also provided real support, though the earnings quality was less clean than the 17% growth rate suggests. Adjusted operating income of $1.276B beat consensus by roughly $59M, and the 84.5% MCR was 50 bps favorable to the Street despite deteriorating by 130 bps year-over-year. Net investment income was $175M, $59M above consensus and $48M above 2Q25. Separately, 50 bps of MCR on $9.66B of premiums equates to approximately $48M of pretax income. Together, those figures show that operating resilience was real, but unusually strong investment income made the magnitude harder to treat as a clean run rate. Management raised Healthcare’s full-year floor by just $25M, to at least $4.55B.
PBS commercial momentum remains healthy; the economics remain under pressure
PBS itself remained the unresolved piece. The segment decline was planned, reflecting large-client renewals and extensions plus investment in Signature. However, PBS tracked modestly below management’s earlier assumptions because GLP-1 growth moderated and some economics moved into Specialty. Evernorth still beat quarterly consensus by about $37M, yet management left its full-year adjusted-income floor unchanged at $6.9 billion and said lower GLP-1 volumes would offset the second-quarter favorability in the back half.
While PBS earnings remain under near-term pressure, retention rates and other forward indicators still appear to be healthy. PBS retention remains above 97% for 2026, preliminary 2027 retention is mid-90s or better, and secured 2027 new business exceeds the prior two selling seasons combined. Cigna plans to move its insured book to Signature in 2027 and at least half of Evernorth PBS members by year-end 2028. Again, this argues for a healthy to strong selling season and retention, but investors will still need to see real stability in the underlying margins and economics before underwriting CI’s long-term targets. Some of that will only come with time.
The market still demands proof
Estimate revisions were concentrated in 2026. CI’s 2026 consensus EPS estimate increased $0.10, from $30.41 on July 29 to $30.51 on August 20, matching the guidance raise. The 2027 estimate was effectively unchanged at $33.47, versus $33.48 before the print. Current estimates imply 9.7% growth in 2027, just below the 10% lower bound of management’s long-term algorithm; using the $30.45 guidance floor as the base produces 9.9%. Analysts incorporated the higher 2026 floor without increasing absolute EPS expectations for 2027.
Source: Koyfin; CI 2024 Investor Day; Graver Research calculations. Data through August 20, 2026.
The stock reaction has been negative, although the entire move since the report should not be attributed to just earnings. CI fell 3.0% on July 30 and declined 7.4% from the July 29 preprint close through August 20, while the S&P 500 gained 4.4% and XLV gained 3.7%. The setup had not been especially demanding versus healthcare: from April 29 through July 29, CI rose only 1.4% while XLV gained 16.4%. CI currently trades at 8.7x NTM earnings, below both its 11.0x 10-year median and its 9.2x negative-one-standard-deviation band. At this valuation, investors do not need a flawless story, but they still need a credible 2027 bridge.
What matters from here
The next thesis-defining event is the September 30 Investor Day. Management needs to show a 2027 bridge in which normalized Specialty growth and continued Healthcare gains more than offset remaining PBS pressure, Signature investment and ACA-exit friction. Formal segment guidance on the fourth-quarter call will be the next confirmation. Evidence of profitable Signature commitments, pricing that keeps pace with elevated medical trend, and FY27 implied EPS growth moving above the 10% low end of the algorithm would strengthen the case. An Evernorth guide cut, continued PBS shortfalls, faster Specialty normalization, worsening Healthcare trend or greater dependence on investment income and buybacks would weaken it. The second quarter established that Cigna’s portfolio can protect earnings while one business resets. The next step is proving that the same portfolio can produce additive growth after the easiest offsets normalize.